Samarth Life Sciences Private Limited - Due diligence report
A 360° intelligence report on Samarth: trust score, financial health, credit view, compliance, directors, growth and distress signals - gene…
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Samarth — 360° Intelligence Report
Generated from MCA filings & public recordsSamarth is assessed as Low Risk with a Trust Score of 91/100. Samarth is an active private limited indian non-government company incorporated in 2014, operating in the Pharma sector. Processed financial statements are not yet available for trend analysis. Based on MCA filings and public records, it currently shows a low compliance risk and low financial risk profile.
Report generated on 03 Jul 2026 from the latest processed filings. Samarth Life Sciences Private Limited snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
Score Card
Higher is safer · rule-based & explainableFinancial Intelligence Dashboard
Consolidated · 1 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
Credit & Compliance Intelligence
Why the scores are what they are- Liabilities ≈ 38% EBITDA - serviceable.
- No open charges - unencumbered balance sheet.
- Working-capital cover adequate.
- Profitable - internal accruals available.
Charges position: 0 open (-) · 0 satisfied (-).
- Company status is Active as per MCA.
- Annual filings current (balance sheet Mar 2025).
- Litigation present in 1 court forum(s).
- 22 active GST registration(s).
Director Intelligence
Stability score: 95/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| KRISHNA MURTHY NARASIMHAPRASAD | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| RAJIV GUNVANTLAL SHAH | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 2 directors on the board.
- No disqualified or deactivated DINs.
- Stable board - no exits in 3 years.
- Average tenure above 5 years.
Ownership & Group Intelligence
As per FY 2022 annual returnPromoters hold a dominant controlling stake - exact percentages are part of the full report.
Key managerial personnel: KRISHNA MURTHY NARASIMHAPRASAD (Whole-time director)
Full shareholding pattern, group structure & capital events →
Risk Intelligence Center
Growth N/A · Distress 90Stakeholder Verdicts
Vendor · Banker · Investor- Statutory record is clean.
- No distress signals on file.
- Financial filings available for verification.
- Debt capacity assessed from filed statements.
- No existing security registered - first-charge position available.
- Compliance record supports lending.
- No clear growth signals in the filed years.
- Margin and return trends computable from filings.
- Management team looks stable.
MCA Filings & Events Timeline
Latest 8 eventsKey Observations
Auto-generated from the data above| Company | CIN | Location |
|---|---|---|
| Tirupati Medicare | U24233DL2005PLC139667 | New Delhi, Delhi, India |
| Fil | U24231JK1989PTC001136 | Jammu And Kashmir, Jammu & Kashmir, India |
| Gautami Oil N Chemicals Private Limited | U15143UP2004PTC028661 | Kanpur, Uttar Pradesh, India |
| Sunita Hydrocolloids Private Limited | U24304GJ2017PTC097944 | Vadodara, Gujarat, India |
| Prabu Soap Works Private Limited | U24290TZ2021PTC036574 | Coimbatore, Tamil Nadu, India |
| Dhanveen Pigments Private Limited | U60231GJ1998PTC034871 | Panoli, Gujarat, India |
| Aptar Pharma India Private Limited | U29195MH1999PTC207807 | Kalyan, Maharashtra, India |
| Dfe Pharma | U24299TN2019FTC129309 | Cuddalore, Tamil Nadu, India |
Who Uses This Report
CA · CS · Banker · Investor · VendorVerify Samarth before audits and certifications: compliance score 93/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Track statutory health of Samarth: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Current banker verdict: Favourable lending indicators. Credit risk score 90/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investor view: Mixed indicators. Growth score n/a, margin trends, ownership structure and peer set for Samarth - screening before a deeper diligence.
Vendor verdict: Favourable indicators. Trust score 91/100, distress signals and MSME payment-delay disclosures - know whether Samarth pays its suppliers before you extend credit terms.
Litigation footprint (1 case(s) on record), regulatory flags, charge documents trail and director networks for Samarth - groundwork for KYC, onboarding and disputes.
Frequently Asked Questions
Is Samarth an active company?
Samarth has MCA status “Active” with a compliance score of 93/100 (Low Risk).
Is Samarth financially healthy?
Samarth has a Financial Health Score of 80/100 (Low Risk) based on its filed financial statements.
Should I do business with Samarth?
Its overall Trust Score is 91/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Samarth?
Promoters hold a dominant controlling stake - exact percentages are in the full report. 2 active director(s) are on record.
Does Samarth have loans or charges against its assets?
No charges are registered against this company - an unencumbered balance sheet.
Is Samarth up to date with its ROC filings?
Annual filings current (balance sheet Mar 2025). Overall compliance score: 93/100 (Low Risk).
Is it risky to lend to Samarth?
Its Credit Risk Score is 90/100 (Low Risk). Banker verdict: Favourable lending indicators.